Original Article

You have full text access to this OnlineOpen article

A Phase I–II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma

  1. Tony S. K. Mok M.D.1,†,*,
  2. Herman Wong M.B.B.S.1,
  3. Benny Zee Ph.D.1,
  4. Kwok Hung Yu M.B.B.S.1,
  5. Thomas W. T. Leung M.D.1,
  6. Tak Wai Lee M.B.B.S.2,
  7. Anthony Yim M.D.2,
  8. Anthony T. C. Chan M.D.1,
  9. Winnie Yeo M.D.1,
  10. Karen Chak R.N.1,
  11. Philip Johnson M.D.1

Article first published online: 17 SEP 2002

DOI: 10.1002/cncr.10836

Issue

Cancer

Cancer

Volume 95, Issue 7, pages 1511–1519, 1 October 2002

Additional Information

How to Cite

Mok, T. S. K., Wong, H., Zee, B., Yu, K. H., Leung, T. W. T., Lee, T. W., Yim, A., Chan, A. T. C., Yeo, W., Chak, K. and Johnson, P. (2002), A Phase I–II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma. Cancer, 95: 1511–1519. doi: 10.1002/cncr.10836

Author Information

  1. 1

    Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China

  2. 2

    Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China

  1. †

    Fax: 852-2648-7097

*Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, China

  1. †

    Fax: 852-2648-7097

Publication History

  1. Issue published online: 17 SEP 2002
  2. Article first published online: 17 SEP 2002
  3. Manuscript Accepted: 17 APR 2002
  4. Manuscript Revised: 12 APR 2002
  5. Manuscript Received: 23 JAN 2002

Funded by

  • GlaxoSmithKline, Hong Kong Ltd.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (87K)

REFERENCES

  • 1
    Lynch T. Topotecan today [editorial]. J Clin Oncol. 1996; 14: 3053–3055.
  • 2
    Schiller JH, Kim K, Hutson P, et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 1996; 14: 2345–2352.
  • 3
    Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a Phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol. 1997; 15: 2090–2096.
  • 4
    Eckardt J, Gralla R, Palmer MC, et al. Topotecan as second-line therapy in patients with small cell lung cancer: a Phase II study [abstract]. Ann Oncol. 1996; 7 (Suppl 5): 513.
  • 5
    von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999; 17: 658–667.
  • 6
    Slevin H, Clark P, Joel S, et al. A randomized trial to evaluate the effect of schedule on activity of etoposide in SCLC. J Clin Oncol. 1989; 7: 1333–1340.
  • 7
    Miller A, Herndon J, Hollis D, et al. Schedule dependency of 21 days oral versus 3 days intravenous cisplatin in extensive stage SCLC: a randomized Phase III study of Cancer and Leukemia Group B. J Clin Oncol. 1995; 13: 1871–1879.
  • 8
    Medical Research Council Lung Cancer Working Party. Comparison of oral etoposide and standard intravenous multi-drug chemotherapy for small cell lung cancer: a stopped multicenter randomized trial. Lancet. 1996; 348: 563–566.
  • 9
    Kaufmann SH. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res. 1991; 51: 1129–1136.
  • 10
    Jonsson E, Fridborg H, Nygren P, Larsson R. Synergistic interactions of combination of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur J Clin Pharmacol. 1998; 54: 509–514.
  • 11
    Cheng MF, Chatterjee S, Berger NA. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res. 1994; 6: 269–279.
  • 12
    Bertrand R, O'Connor PM, Kerrigan D, Pommier Y. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer. 1992; 28A: 743–748.
  • 13
    Booner JA, Kozelsky TF. The significance of the sequence of administration to topotecan and etoposide. Cancer Chemother Pharmacol. 1996; 39: 109–112.
  • 14
    Tan KB, Mattern MR, Eng WK, McCabe FL, Johnson RK. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst. 1989; 81: 1732–1735.
  • 15
    Crump M, Lipton J, Hedley D, et al. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group study. Leukemia. 1999; 13: 343–347.
  • 16
    Vey N, Kantarjian H, Beran M, et al. Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized Phase I/II study. Invest New Drugs. 1999; 17: 89–95.
  • 17
    Herben VM, ten Bokkel Huinink WE, Dubbelman AC, et al. Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. Br J Cancer. 1997; 76: 1500–1508.
  • 18
    Hammond LA, Eckardt JR, Ganapathi R, et al. A Phase I and translation study of sequential administration of topoisomerase I and II inhibitors topotecan and etoposide. Clin Cancer Res. 1998; 4: 1459–1467.
  • 19
    Dowlati A, Levitan N, Gordon NH, et al. Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2001; 47: 141–148.
  • 20
    Buchholz E, Drings P, Mayer U, Weiser S, Manegold C. Lung cancer sequential administration of topotecan and etoposide in extensive small cell lung cancer—a Phase I study [abstract]. Proc Am Soc Clin Oncol. 2001; 19: 2156.
  • 21
    Gervais R, Quoix E, Mattson K, et al. Randomised Phase II study of topotecan/cisplatin versus topotecan/etoposide in patients with untreated, extensive disease, small cell lung cancer [abstract]. Lung Cancer. 2000; 29(S1): 163.
  • 22
    Brookmeyer R, Crowley J. A confidence interval for median survival time. Biometric. 1982; 38: 29–41.
  • 23
    Aisner J, Alberto P, Bitran J, et al. Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer Workshop. Cancer Treat Rep. 1983; 67: 37–48.
  • 24
    Bonner JA, Sloan JA, Shanahan TG, et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung cancer. J Clin Oncol. 1999; 17: 2681–2691.
  • 25
    Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol. 1997; 15: 893–900.
  • 26
    Johnson BE, Bridges JD, Sobczeck M, et al. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol. 1996; 14: 806–813.
  • 27
    Clark P, Cottier B. The activity of 10 days, 14 days, and 21 days schedules of single agent etoposide in previously untreated patient with extensive small cell lung cancer. Semin Oncol. 1993; 19: 36–39.
  • 28
    von Pawel J, Gatzemeier U, Pujol JL, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol. 2001; 19: 1743–1749.
  • 29
    Eckardt JR, Palmer MC, Fanucchi MP, et al. Single agent oral topotecan as first-line treatment for patients with extensive disease small cell lung cancer ineligible for standard therapy: a Phase II study [abstract]. Lung Cancer. 2000; 29(S1): 25.
  • 30
    Fujiwara Y, Ohune T, Okusaki K, et al. Bioavailability of 50-mg and 750-mg oral etoposide in lung cancer patients. Cancer Chemother Pharmacol. 1996; 37: 327–331.
  • 31
    Hande KR, Krozely MG, Greco FA, Hainsworth JD, Johnson DH. Bioavailability of low-dose oral etoposide. J Clin Oncol. 1993; 11: 374–377.
  • 32
    Huisman C, Postmus PE, Giaccone G, Smit EF. A dose and schedule finding study of sequential intravenous topotecan and etoposide in small cell and non-small cell lung cancer patients [abstract]. Proc Am Soc Clin Oncol. 2001; 19: 401.
View Full Article (HTML) Get PDF (87K)